Full-Time

Associate Director

Digital Product Management, Catalyst

Updated on 9/14/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$188.1k - $254.4k/yr

+ Annual bonus + Stock-based long-term incentives

Remote in USA

Remote

Bachelor's, Master's, PhD, Associate's

Category
Product (1)
Required Skills
LLM
Product Management

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree and 3 years of experience in Digital Product, Product Management, Product Leadership, Digital Transformation, Technology Strategy, or a related area; or a master's degree and 5 years of such experience; or a bachelor's degree and 7 years of such experience; or an associate's degree and 12 years of such experience; or a high school diploma/GED and 14 years of such experience.
Responsibilities
  • Embed with complex, high-priority products and related product teams to improve product management practices and accelerate Digital Product Operating Model adoption.
  • Serve as a senior hands-on player-coach to Digital Product Managers and cross-functional team members.
  • Coach Digital Product Managers on complex problem framing, continuous discovery, product strategy, outcome-based roadmaps, OKRs, KPIs, investment trade-offs, stakeholder alignment, and value measurement.
  • Temporarily perform product management responsibilities when no Digital Product Manager is assigned, including shaping product direction, aligning stakeholders, defining outcomes, and supporting roadmap, capacity, and prioritization decisions.
  • Coach teams to combine user insights, product data, business context, and experimentation to make evidence-based product decisions.
  • Help cross-functional teams understand and apply Digital Product Operating Model practices in complex product environments.
  • Partner with business, technology, business analysis, design, data, compliance, quality, and adjacent product teams to strengthen product ways of working.
  • Help teams clarify roles, decision rights, operating rhythms, success measures, dependencies, and expectations within the Digital Product Operating Model.
  • Identify product management capability gaps, adoption barriers, and recurring anti-patterns across complex product environments.
  • Support teams in building durable product habits that continue after the Catalyst engagement ends.
  • Connect enterprise and business-unit strategy to product strategy and translate strategic objectives into product outcomes and investment decisions.
  • Help teams frame complex user and business problems and connect product work to measurable outcomes.
  • Support development of product vision, strategy, roadmaps, OKRs, KPIs, investment recommendations, and value-realization plans.
  • Guide trade-off recommendations based on user needs, business value, feasibility, risk, capacity, dependencies, and enterprise priorities.
  • Support discovery, validation, and learning practices in ambiguous environments.
  • Help teams improve roadmap quality by shifting from feature and output lists to problem-, opportunity-, and outcome-oriented roadmaps.
  • Identify and help resolve cross-product dependencies, sequencing challenges, and prioritization conflicts.
  • Influence senior stakeholders and adjacent product teams without formal authority.
  • Communicate product direction, adoption progress, trade-offs, risks, and required decisions to team-level and senior stakeholders.
  • Help teams align near-term delivery decisions with longer-term product strategy and measurable outcomes.
  • Escalate major blockers, trade-offs, or alignment issues to the Director, Product Management Catalysts.
  • Execute the Catalyst engagement model, including product/team assessment, engagement planning, embedded coaching, adoption measurement, transition planning, and learning capture.
  • Contribute to refinement of the Catalyst model based on practical learnings from complex embedded engagements.
  • Define and track engagement success measures, including capability growth, cross-functional adoption, product maturity, product outcomes, and sustained Digital Product Operating Model adoption.
  • Surface insights, risks, and recommendations to Product Management Catalysts and Product Management Hub leadership.
  • Translate lessons from embedded work into reusable examples, practices, templates, and playbook improvements.
Desired Qualifications
  • At least 7 years of progressive experience in digital product management, including product strategy, discovery, roadmapping, prioritization, delivery, and outcome measurement.
  • Experience owning or leading complex, interdependent, high-priority products or product initiatives.
  • Experience coaching, mentoring, or upskilling product managers, product owners, business partners, and cross-functional team members.
  • Strong product management craft involving user and customer problem definition, product discovery, roadmap development, OKRs, KPIs, prioritization, stakeholder alignment, investment trade-off recommendations, and value realization.
  • Experience influencing senior business, technology, product, engineering, data, compliance, and adjacent product stakeholders without formal authority.
  • Ability to operate as a senior hands-on player-coach while balancing direct product leadership with coaching and capability building.
  • Ability to help teams shift from output-oriented delivery to outcome-oriented product management.
  • Strong judgment in ambiguous environments, including framing complex problems, resolving dependencies, making trade-off recommendations, and creating practical paths forward.
  • Experience contributing to product operating models, playbooks, standards, templates, training, or adoption approaches.
  • Experience in healthcare, biotechnology, or other regulated industries; candidates from high-tech, digital, consulting, or product-led organizations are also encouraged to apply.
  • Familiarity with artificial intelligence-native product development, generative artificial intelligence workflows, responsible artificial intelligence principles, and the evolving role of artificial intelligence in product management.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.